Originally published as JCO Early Release 10.1200/JCO.2007.10.9777 on June 18 2007
Journal of Clinical Oncology, Vol 25, No 25 (September 1), 2007: pp. 3991-4008
© 2007 American Society of Clinical Oncology.
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
Joseph R. Carver,
Charles L. Shapiro,
Andrea Ng,
Linda Jacobs,
Cindy Schwartz,
Katherine S. Virgo,
Karen L. Hagerty,
Mark R. Somerfield,
David J. Vaughn for the ASCO Cancer Survivorship Expert Panel
From the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Ohio State University Comprehensive Cancer Center, Columbus, OH; Brigham and Women's Hospital, Boston, MA; Brown University, Providence, RI; St Louis University Medical Center & Department of Veterans Affairs Medical Center, St Louis, MO; and the American Society of Clinical Oncology, Alexandria, VA
Address reprint requests to the American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org
Purpose To review the evidence on the incidence of long-term cardiac or pulmonary toxicity secondary to chemotherapy, radiotherapy, or trastuzumab in symptomatic and asymptomatic cancer survivors.
Methods An American Society of Clinical Oncology Panel reviewed pertinent information from the literature through February 2006.
Results Few studies directly addressing the benefits of screening for long-term cardiac or pulmonary toxicity in asymptomatic cancer survivors who received chemotherapy, radiotherapy, or trastuzumab were identified. The reviewed literature included primarily retrospective and cross-sectional studies describing the incidence of cardiac and pulmonary late effects. Anatomic and/or functional abnormalities have been associated with use of all currently available anthracyclines and their derivatives. Trastuzumab-related cardiac dysfunction rarely causes death, and in most cases is reversible with improvement in cardiac function on drug discontinuation and/or treatment with cardiac medications. The estimated aggregate incidence of radiation-induced cardiac disease is 10% to 30% by 5 to 10 years post-treatment, although the incidence may be lower with modern techniques. Radiation pneumonitis is reported in 5% to 15% of lung cancer patients receiving definitive external-beam radiation therapy. A minority of patients may develop progressive pulmonary fibrosis; late complications include cor pulmonale and respiratory failure. Bleomycin-induced pneumonitis is an acute rather than late effect of treatment. Late pulmonary complications in bone marrow or stem cell transplantation patients who develop interstitial pneumonitis include idiopathic pneumonia syndrome and bronchiolitis obliterans.
Conclusion An increased incidence of cardiac and/or pulmonary dysfunction is observed in cancer survivors. Research is needed to identify high-risk patients, and to determine the optimal screening strategies and subsequent treatment.
published online ahead of print at www.jco.org on June 18, 2007.
J.R.C., C.L.S., A.N., and D.J.V. are members of the writing committee.
C.L.S. and D.J.V. are co-chairs of the American Society of Clinical Oncology Cancer Survivorship Expert Panel.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Editorial
- Cancer Survivorship Research and Guidelines: Maybe the Cart Should Be Beside the Horse
Craig C. Earle
JCO 2007 25: 3800-3801
[Full Text]
Related Correspondence
- Clinical Management of Long-Term Cancer Survivors
Cecilia Simonelli, Massimiliano Berretta, Umberto Tirelli, and Maria A. Annunziata
JCO 2008 26: 161-162
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
A. B. Chen, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng
Cost Effectiveness and Screening Interval of Lipid Screening in Hodgkin's Lymphoma Survivors
J. Clin. Oncol.,
November 10, 2009;
27(32):
5383 - 5389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Jacobs, S. C. Palmer, L. A. Schwartz, A. DeMichele, J. J. Mao, J. Carver, C. Gracia, C. E. Hill-Kayser, J. M. Metz, M. K. Hampshire, et al.
Adult Cancer Survivorship: Evolution, Research, and Planning Care
CA Cancer J Clin,
November 1, 2009;
59(6):
391 - 410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Schwartz, L. S. Constine, D. Villaluna, W. B. London, R. E. Hutchison, R. Sposto, S. E. Lipshultz, C. S. Turner, P. A. deAlarcon, and A. Chauvenet
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
Blood,
September 3, 2009;
114(10):
2051 - 2059.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Recht, M. Ancukiewicz, M. A. Alm El-Din, X.-Q. Lu, C. Martin, S. M. Berman, A. E. Hirsch, L. A. Kachnic, A. Katz, S. MacDonald, et al.
Lung Dose-Volume Parameters and the Risk of Pneumonitis for Patients Treated With Accelerated Partial-Breast Irradiation Using Three-Dimensional Conformal Radiotherapy
J. Clin. Oncol.,
August 20, 2009;
27(24):
3887 - 3893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. D. Ferris, E. Bruera, N. Cherny, C. Cummings, D. Currow, D. Dudgeon, N. JanJan, F. Strasser, C. F. von Gunten, and J. H. Von Roenn
Palliative Cancer Care a Decade Later: Accomplishments, the Need, Next Steps--From the American Society of Clinical Oncology
J. Clin. Oncol.,
June 20, 2009;
27(18):
3052 - 3058.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, and M. W. Verrill
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Ann. Onc.,
May 1, 2009;
20(5):
816 - 827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A Heidenreich and J. R Kapoor
Radiation induced heart disease
Heart,
February 1, 2009;
95(3):
252 - 258.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tachimori, N. Kanamori, N. Uemura, N. Hokamura, H. Igaki, and H. Kato
Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma.
J. Thorac. Cardiovasc. Surg.,
January 1, 2009;
137(1):
49 - 54.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M L Irwin
Physical activity interventions for cancer survivors
Br. J. Sports Med.,
January 1, 2009;
43(1):
32 - 38.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lustberg and C. L. Shapiro
Physical Challenges of Adult Cancer Survivors
ASCO Educational Book,
January 1, 2009;
2009(1):
564 - 569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer
Anthracycline Cardiotoxicity: From Bench to Bedside
J. Clin. Oncol.,
August 1, 2008;
26(22):
3777 - 3784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Armenian and S. Bhatia
Cardiovascular disease after hematopoietic cell transplantation - lessons learned
Haematologica,
August 1, 2008;
93(8):
1132 - 1136.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bhatia and L. L. Robison
Cancer Survivorship Research: Opportunities and Future Needs for Expanding the Research Base
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2008;
17(7):
1551 - 1557.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Carver, S. J. Schuster, and J. H. Glick
Doxorubicin Cardiotoxicity in the Elderly: Old Drugs and New Opportunities
J. Clin. Oncol.,
July 1, 2008;
26(19):
3122 - 3124.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Simonelli, M. A. Annunziata, E. Chimienti, M. Berretta, and U. Tirelli
Cancer survivorship: a challenge for the European oncologists
Ann. Onc.,
July 1, 2008;
19(7):
1216 - 1217.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E Lipshultz, J. A Alvarez, and R. E Scully
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Heart,
April 1, 2008;
94(4):
525 - 533.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pant, M. B. Landon, M. Blumenfeld, W. Farrar, and C. L. Shapiro
Treatment of Breast Cancer With Trastuzumab During Pregnancy
J. Clin. Oncol.,
March 20, 2008;
26(9):
1567 - 1569.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Ganz, M. A. Hussey, C. M. Moinpour, J. M. Unger, L. F. Hutchins, S. R. Dakhil, J. K. Giguere, J. W. Goodwin, S. Martino, and K. S. Albain
Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897
J. Clin. Oncol.,
March 10, 2008;
26(8):
1223 - 1230.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Simonelli, M. Berretta, U. Tirelli, and M. A. Annunziata
Clinical Management of Long-Term Cancer Survivors
J. Clin. Oncol.,
January 1, 2008;
26(1):
161 - 162.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. Haston, M. Begin, G. Dorion, and S. M. Cory
Distinct Loci Influence Radiation-Induced Alveolitis from Fibrosing Alveolitis in the Mouse
Cancer Res.,
November 15, 2007;
67(22):
10796 - 10803.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Earle
Cancer Survivorship Research and Guidelines: Maybe the Cart Should Be Beside the Horse
J. Clin. Oncol.,
September 1, 2007;
25(25):
3800 - 3801.
[Full Text]
[PDF]
|
 |
|
|